Microsphere based Tolerogenic antigen presentation system
Microsphere based Tolerogenic antigen presentation system
批准号:
7244119
负责人:
CHENTHAMARAKSHAN VASU
金额:
$22.58万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-06-01 至 2008-05-31
关键词:
AdoptedAllergicAntibodiesAntigen PresentationAntigen ReceptorsAntigensAttentionAttenuatedAutoantigensAutoimmune DiabetesAutoimmune DiseasesAutoimmune ProcessAutoimmunityBindingBiodegradable microsphereBiological ModelsBlocking AntibodiesCD28 geneCD4 Positive T LymphocytesCD80 geneCD8B1 geneCell SizeCellsChildChildhoodClinicalComplexConditionDendritic CellsDiseaseEffectivenessEffector CellEpitopesFamilyFigs - dietaryFrightGenerationsGoalsGraft RejectionHomeostasisHomologous GeneHumanImmuneImmune responseImmunologyImmunosuppressionImmunotherapeutic agentIn VitroInbred NOD MiceInjectableInsulin-Dependent Diabetes MellitusLearningLifeLigandsLigationLiteratureMHC Class II GenesMediatingMicrospheresMindModelingMolecular TargetMusNatureNumbersOrganOvumPathway interactionsPeptide/MHC ComplexPeptidesPhenotypePhysiologic pulsePlayPulse takingReagentRecombinantsResearchResearch PersonnelRoleSignal PathwaySignal TransductionSpecificityStagingSurfaceSystemT-Cell ActivationT-Cell ReceptorT-LymphocyteTestingTherapeuticTherapeutic immunosuppressionThinkingTo autoantigenTransgenic MiceTransgenic ModelTransplantationbasecytokinedesigndiabeticdimerin vivoinhibitor/antagonistmouse modelnovelnovel strategiespeptide Ipreventreceptorresearch studyresponsesurface coatingtherapeutic target
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Understanding of T cell activation and costimulatory mechanisms have led to the identification of novel molecular targets for the treatment of various immunological disorders. Since costimulatory pathways are considered to be essential for T cell activation and differentiation, manipulating co-stimulatory signals on antigen encountered T cells has been considered as an attractive approach for inducing antigen specific tolerance. Two approaches are well adopted in inducing tolerance. Firstly, disrupting T cell activation using blocking antibodies or soluble receptors has often induced tolerance to antigens. Second approach is through exploiting the signaling of T cell negative regulators. Negative regulators that are upregulated significantly on activated T cells have been the molecules of attention in last several years. CTLA-4, PD-1 and BTLA are the three major T cell negative regulators identified and explored as the targets for inducing T cell tolerance. There are other ligands with unknown negative regulators on activated T cells. Induction of antigen specific tolerance depends on concurrent engagement of the T cell receptor (TCR) and these negative regulators. We and others have successfully demonstrated this both in vitro and in vivo. Designing flexible and effective system for this co-ligation is the next step towards achieving the goal of using costimulatory control as antigen specific tolerance induction strategy for clinical use. Our hypothesis is that engaging multiple negative regulators on T cells along with TCR on antigen specific T cells will be necessary and sufficient to induce effective antigen specific tolerance. We propose to generate injectable biodegradable microspheres coated with recombinant MHC-peptides and ligands of T cell negative regulators as tolerogenic antigen presenting system to induce antigen specific T cell tolerance. This study will be aimed at: 1) testing the potential of microsphere bound MHC-dimer peptide complex and negative regulatory ligands in inducing effective antigen specific tolerance using TCR-transgenic mice, and 2) exploring the potential of tolerogenic microsphere based antigen presenting system in preventing and treating autoimmune diabetes using NOD mouse model. The results from this study will help us design an effective antigen specific immunotherapeutic approach that can be used to treat or prevent autoimmune diseases, like childhood type 1 diabetes and other immune mediated disorders through tolerance induction and regulatory T cell induction.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1080/08916934.2021.2012165
发表时间:
2022-03
期刊:
Autoimmunity
影响因子:
3.5
作者:
[]
通讯作者:
DOI:
10.1111/imm.13476
发表时间:
2022-07
期刊:
Immunology
影响因子:
6.4
作者:
[]
通讯作者:
Modulation of dendritic cells using granulocyte-macrophage colony-stimulating factor (GM-CSF) delays type 1 diabetes by enhancing CD4+CD25+ regulatory T cell function.
使用粒细胞巨噬细胞刺激因子(GM-CSF)调节树突状细胞,通过增强CD4+ CD25+调节性T细胞功能,通过增强1型糖尿病。
DOI:
10.1016/j.clim.2008.12.001
发表时间:
2009-05
期刊:
Clinical immunology (Orlando, Fla.)
影响因子:
--
作者:
[Cheatem D, Ganesh BB, Gangi E, Vasu C, Prabhakar BS]
通讯作者:
Prabhakar BS
DOI:
10.4049/jimmunol.181.12.8323
发表时间:
2008-12-15
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
作者:
[Karumuthil-Melethil S, Perez N, Li R, Vasu C]
通讯作者:
Vasu C
Identification and Functional Characterization of Bioactive Microbial Metabolites of Beta-Glucan Degradation
-
批准号:10651978
-
项目类别:
-
资助金额:$69.61万
-
财政年份:2023
-
负责人:CHENTHAMARAKSHAN VASU
-
依托单位:
Role of microbiota-TLR7/8 Interaction in systemic lupus erythematosus
-
批准号:10261075
-
项目类别:
-
资助金额:$7.56万
-
财政年份:2018
-
负责人:CHENTHAMARAKSHAN VASU
-
依托单位:
Role of microbiota-TLR7/8 Interaction in systemic lupus erythematosus
-
批准号:10462246
-
项目类别:
-
资助金额:$8.64万
-
财政年份:2018
-
负责人:CHENTHAMARAKSHAN VASU
-
依托单位:
Role of microbiota-TLR7/8 Interaction in systemic lupus erythematosus
-
批准号:10291401
-
项目类别:
-
资助金额:$69.97万
-
财政年份:2018
-
负责人:CHENTHAMARAKSHAN VASU
-
依托单位:
Role of microbiota-TLR7/8 Interaction in systemic lupus erythematosus
-
批准号:10520068
-
项目类别:
-
资助金额:$69.97万
-
财政年份:2018
-
负责人:CHENTHAMARAKSHAN VASU
-
依托单位:
Administrative Supplement - Role of microbiota-TLR7/8 Interaction in systemic lupus erythematosus
-
批准号:10120039
-
项目类别:
-
资助金额:$21.61万
-
财政年份:2018
-
负责人:CHENTHAMARAKSHAN VASU
-
依托单位:
Role of microbiota-TLR7/8 Interaction in systemic lupus erythematosus
-
批准号:10051383
-
项目类别:
-
资助金额:$69.97万
-
财政年份:2018
-
负责人:CHENTHAMARAKSHAN VASU
-
依托单位:
Dendritic cell directed T cell negative regulation for treating autoimmunity
-
批准号:8334865
-
项目类别:
-
资助金额:$32.86万
-
财政年份:2009
-
负责人:CHENTHAMARAKSHAN VASU
-
依托单位:
Dendritic cell directed T cell negative regulation for treating autoimmunity
-
批准号:8015582
-
项目类别:
-
资助金额:$3.5万
-
财政年份:2009
-
负责人:CHENTHAMARAKSHAN VASU
-
依托单位:
Dendritic cell directed T cell negative regulation for treating autoimmunity
-
批准号:7776898
-
项目类别:
-
资助金额:$38.86万
-
财政年份:2009
-
负责人:CHENTHAMARAKSHAN VASU
-
依托单位:
Dendritic cell directed T cell negative regulation for treating autoimmunity
-
批准号:7655015
-
项目类别:
-
资助金额:$39.25万
-
财政年份:2009
-
负责人:CHENTHAMARAKSHAN VASU
-
依托单位:
Dendritic cell directed T cell negative regulation for treating autoimmunity
-
批准号:8416980
-
项目类别:
-
资助金额:$33.97万
-
财政年份:2009
-
负责人:CHENTHAMARAKSHAN VASU
-
依托单位:
Dendritic cell directed T cell negative regulation for treating autoimmunity
-
批准号:8211052
-
项目类别:
-
资助金额:$36.14万
-
财政年份:2009
-
负责人:CHENTHAMARAKSHAN VASU
-
依托单位:
Microsphere based Tolerogenic antigen presentation system
-
批准号:7115619
-
项目类别:
-
资助金额:$19.38万
-
财政年份:2006
-
负责人:CHENTHAMARAKSHAN VASU
-
依托单位:
Generation of antigen specific regulatory T cells
-
批准号:6759532
-
项目类别:
-
资助金额:$23.25万
-
财政年份:2004
-
负责人:CHENTHAMARAKSHAN VASU
-
依托单位:
Generation of antigen specific regulatory T cells
-
批准号:6870226
-
项目类别:
-
资助金额:$19.38万
-
财政年份:2004
-
负责人:CHENTHAMARAKSHAN VASU
-
依托单位:
海外基金